2.12
+0.05(+2.42%)
Currency In USD
| Previous Close | 2.07 |
| Open | 2.08 |
| Day High | 2.18 |
| Day Low | 2.04 |
| 52-Week High | 4.97 |
| 52-Week Low | 1.35 |
| Volume | 1.04M |
| Average Volume | 2.09M |
| Market Cap | 127.09M |
| PE | -1.63 |
| EPS | -1.3 |
| Moving Average 50 Days | 1.78 |
| Moving Average 200 Days | 2.71 |
| Change | 0.05 |
If you invested $1000 in Eledon Pharmaceuticals, Inc. (ELDN) 10 years ago, it would be worth $2.6 as of January 19, 2026 at a share price of $2.12. Whereas If you bought $1000 worth of Eledon Pharmaceuticals, Inc. (ELDN) shares 5 years ago, it would be worth $138.74 as of January 19, 2026 at a share price of $2.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
GlobeNewswire Inc.
Jan 08, 2026 9:05 PM GMT
Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary results from first six patients with type 1 d
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at the upcoming 37th Annual Pip
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
GlobeNewswire Inc.
Nov 18, 2025 9:05 PM GMT
IRVINE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplant Institute